Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04292730 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,113
- Enrollment target
NCT04292730 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 1,113 participants.
The verdict
NCT04292730, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,113 participants
- Enrollment target
Study Summary
The primary objective of this study was to evaluate the efficacy of 2 remdesivir (RDV) regimens compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale on Day 11.
Interventions
- DRUG Standard of Care
- DRUG Remdesivir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,113 participants |
| Start Date | 2020-03-15 |
| Est. Completion | 2020-06-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04292730
The ClinicalTrials.gov registry entry for NCT04292730 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT04292730 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04292730 about?
NCT04292730 is a clinical study titled "Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment". The primary objective of this study was to evaluate the efficacy of 2 remdesivir (RDV) regimens compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale on Day 11.
What is the current status of trial NCT04292730?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,113 participants. The study started on 2020-03-15. Estimated completion is 2020-06-26.
What interventions are being tested in trial NCT04292730?
The interventions under investigation include: Standard of Care (DRUG), Remdesivir (DRUG).
Who is sponsoring clinical trial NCT04292730?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.